KMT2A and acute lymphoblastic leukemia: We matched the results from ALL/MLL- vs AML/MLL- (L2 comparison: 1378 upregulated probes in the former group, 754 upregulated in the latter) and ALL/MLL+ vs AML/MLL+ (L4 comparison: 379 overexpressed in the first group, 601 overexpressed in the second), obtaining 622 shared phenotype-specific probe sets from 2132 (L2) and 980 (L4) differentially expressed markers [see Additional File 2].